• 54,646+ CME Conference Registrations Sold
  • 163,937+ Medical Conferences
  • 284 Specialties
  • 11,702 Organizers
  • 159,405 Speakers
  • 159 Countries
  • 4,842 Cities
Home  >  Speakers  >  Tomoyuki Igawa
Tomoyuki Igawa

Tomoyuki Igawa

Chief Executive Officer, Head | Singapore, Singapore    Singapore
Biotechnology, Chemistry,...More
Spoken at 2 events

Biography :

Tomoyuki Igawa, Ph.D., is currently the Chief Executive Officer of Chugai Pharamabody Research in Singapore. He has started working at Chugai Pharmaceutical as a Research scientist and had experiences as a project leader for emicizumab and natalizumab. He graduated and awarded PhD from the University of Tokyo for studies in Engineering, Chemistry and Biotechnology.

After a couple of year as Research Scientist working on early CMC development and pharmacokinetics, he focused on antibody engineering which leads to the discovery of bispecific antibody Hemlibra (emicizumab) for haemophilia A, recycling antibody and sweeping antibody technology for various applications. Recent years he has been responsible for biologics drug discovery and cancer immunotherapy discovery. Dr.Igawa likes to work in the area of an interface between antibody technology and disease mechanism especially for unmet needs in the world.

*** **** ****
For speaker's contact information - Contact us



Interested Topics

Biotechnology, Chemistry, Research and Development, Pharmacokinetics, Antibody Engineering, Biologics Drug Discovery, Cancer Immunotherapy, Biopharmaceuticals, Technology Transfer

State Licenses

This section has yet to be updated by the speaker.

Board Certifications

This section has yet to be updated by the speaker.

Professional Association

This section has yet to be updated by the speaker.



Conference Session Materials

The conference session material has yet to be added by the speaker.

Send Message

Onsite to Virtual Conference

Market your online event to Million plus Healthcare professionals.